BioMarin Pharmaceutical Inc. or Verona Pharma plc: Who Invests More in Innovation?

BioMarin leads in R&D investment over Verona Pharma.

__timestampBioMarin Pharmaceutical Inc.Verona Pharma plc
Wednesday, January 1, 20144615430004101058
Thursday, January 1, 201563480600010763215
Friday, January 1, 20166619050005579049
Sunday, January 1, 201761075300032051299
Monday, January 1, 201869632800024482286
Tuesday, January 1, 201971500700043892589
Wednesday, January 1, 202062811600044505000
Friday, January 1, 202162879300079406000
Saturday, January 1, 202264960600049283000
Sunday, January 1, 202374677300017282730
Monday, January 1, 2024747184000
Loading chart...

In pursuit of knowledge

Innovation Investment: BioMarin vs. Verona Pharma

In the competitive world of pharmaceuticals, innovation is key. BioMarin Pharmaceutical Inc. and Verona Pharma plc are two companies that have consistently invested in research and development (R&D) to drive innovation. From 2014 to 2023, BioMarin has shown a robust commitment to R&D, with expenses peaking in 2023 at approximately $747 million. This represents a significant increase of around 62% from their 2014 investment. In contrast, Verona Pharma's R&D spending, while growing, remains modest in comparison, with a peak of about $79 million in 2021. This is a substantial increase from their 2014 figure, reflecting a nearly 19-fold rise. The data highlights BioMarin's dominant position in innovation investment, consistently outspending Verona Pharma by a wide margin. As the pharmaceutical landscape evolves, these investments could be pivotal in shaping the future of medical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025